393 related articles for article (PubMed ID: 11759185)
1. Focus on ziprasidone.
Green B
Curr Med Res Opin; 2001; 17(2):146-50. PubMed ID: 11759185
[TBL] [Abstract][Full Text] [Related]
2. Brief report on Ziprasidone.
Firoz AH; Rahman AH; Chowdhury WA; Mamun AA
Mymensingh Med J; 2002 Jul; 11(2):129-32. PubMed ID: 12395687
[TBL] [Abstract][Full Text] [Related]
3. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice.
Stahl SM; Shayegan DK
J Clin Psychiatry; 2003; 64 Suppl 19():6-12. PubMed ID: 14728084
[TBL] [Abstract][Full Text] [Related]
4. From clinical research to clinical practice: a 4-year review of ziprasidone.
Nemeroff CB; Lieberman JA; Weiden PJ; Harvey PD; Newcomer JW; Schatzberg AF; Kilts CD; Daniel DG
CNS Spectr; 2005 Nov; 10(11 Suppl 17):1-20. PubMed ID: 16381088
[TBL] [Abstract][Full Text] [Related]
5. Oral ziprasidone in the treatment of schizophrenia: a review of short-term trials.
Kane JM
J Clin Psychiatry; 2003; 64 Suppl 19():19-25. PubMed ID: 14728086
[TBL] [Abstract][Full Text] [Related]
6. Ziprasidone and cognition: the evolving story.
Harvey PD
J Clin Psychiatry; 2003; 64 Suppl 19():33-9. PubMed ID: 14728088
[TBL] [Abstract][Full Text] [Related]
7. Maintaining symptom control: review of ziprasidone long-term efficacy data.
Schooler NR
J Clin Psychiatry; 2003; 64 Suppl 19():26-32. PubMed ID: 14728087
[TBL] [Abstract][Full Text] [Related]
8. [Ziprasidone. A new second-generation antipsychotic agent].
Lublin HK
Ugeskr Laeger; 2004 Mar; 166(14):1334-9. PubMed ID: 15101124
[No Abstract] [Full Text] [Related]
9. Ziprasidone (Geodon) for schizophrenia.
Med Lett Drugs Ther; 2001 Jun; 43(1106):51-2. PubMed ID: 11402259
[No Abstract] [Full Text] [Related]
10. Switching among antipsychotics in everyday clinical practice: focus on ziprasidone.
Rossi A; Cañas F; Fagiolini A; Larmo I; Levy P; Montes JM; Papageorgiou G; Sturlason R; Zink M; Correll CU
Postgrad Med; 2011 Jan; 123(1):135-59. PubMed ID: 21293094
[TBL] [Abstract][Full Text] [Related]
11. Intramuscular ziprasidone: moving beyond the conventional in the treatment of acute agitation in schizophrenia.
Brook S
J Clin Psychiatry; 2003; 64 Suppl 19():13-8. PubMed ID: 14728085
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
Ratner Y; Gibel A; Yorkov V; Ritsner MS
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1401-9. PubMed ID: 17669574
[TBL] [Abstract][Full Text] [Related]
13. Introduction. Ziprasidone in schizophrenia: from acute treatment to long-term management.
Kane JM
J Clin Psychiatry; 2003; 64 Suppl 19():3-5. PubMed ID: 14728083
[No Abstract] [Full Text] [Related]
14. A 6-month prospective, observational, naturalistic, uncontrolled study to evaluate the effectiveness and tolerability of oral ziprasidone in patients with schizophrenia.
Arango C; Gómez-Beneyto M; Brenlla J; Gastó C; Sarramea-Crespo F; Chamorro L; Masramon X; Díez T;
Eur Neuropsychopharmacol; 2007; 17(6-7):456-63. PubMed ID: 17234389
[TBL] [Abstract][Full Text] [Related]
15. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group.
Daniel DG; Zimbroff DL; Potkin SG; Reeves KR; Harrigan EP; Lakshminarayanan M
Neuropsychopharmacology; 1999 May; 20(5):491-505. PubMed ID: 10192829
[TBL] [Abstract][Full Text] [Related]
16. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.
Cutler AJ; Kalali AH; Weiden PJ; Hamilton J; Wolfgang CD
J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S20-8. PubMed ID: 18334909
[TBL] [Abstract][Full Text] [Related]
17. Spotlight on ziprasidone in schizophrenia and schizoaffective disorder.
Gunasekara NS; Spencer CM; Keating GM
CNS Drugs; 2002; 16(9):645-52. PubMed ID: 12153335
[TBL] [Abstract][Full Text] [Related]
18. Strategies for successful clinical management of schizophrenia with ziprasidone.
Fagiolini A; Cañas F; Gallhofer B; Larmo I; Levy P; Montes JM; Papageorgiou G; Zink M; Rossi A
Expert Opin Pharmacother; 2010 Sep; 11(13):2199-220. PubMed ID: 20658947
[TBL] [Abstract][Full Text] [Related]
19. Switching from conventional antipsychotics to ziprasidone: a randomized, open-label comparison of regimen strategies.
Stip E; Zhornitsky S; Potvin S; Tourjman V
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):997-1000. PubMed ID: 20470848
[TBL] [Abstract][Full Text] [Related]
20. Combination of ziprasidone and clozapine in treatment-resistant schizophrenia.
Zink M; Mase E; Dressing H
Hum Psychopharmacol; 2004 Jun; 19(4):271-3. PubMed ID: 15181656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]